Fetal cystoscopy to unblock severe bladder outlet obstruction before birth
Official title: Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO): A Prospective Trial
Run by University of Miami · NCT03281798 · Data updated 2026-11-12
This procedure will try fetal cystoscopy in pregnant women carrying a male fetus with severe lower urinary tract obstruction and low amniotic fluid to see if it improves fetal kidney function and chances of survival.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 10 (estimated) |
| Sponsor | University of Miami Academic / other |
| Locations | 2 sites (Miami, Florida and 1 other locations) |
| Status | Recruiting |
| Started | January 1, 2018 |
| Main results expected | August 1, 2028 |
| Study ends | August 1, 2028 |
| Registry record updated | February 24, 2026 |
| Trial ID | NCT03281798 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pregnant women aged 18 or older with a singleton male fetus diagnosed with isolated severe LUTO (dilated bladder, keyhole sign, bilateral hydronephrosis), oligohydramnios, favorable fetal urine electrolytes, normal karyotype, and gestational age between 16 0/7 and 25 6/7 weeks who have considered and declined termination.
✕Probably not a fit
Patients with abnormal fetal urine biochemistry suggesting poor renal prognosis, chromosomal or other major anomalies, prior in utero urinary interventions, multifetal pregnancies, female fetuses, or those outside the gestational window are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional program uses a fetoscope to perform fetal cystoscopy with the aim of visualizing and, when possible, relieving severe bladder outlet obstruction in utero. Pregnant women with a singleton male fetus showing a dilated bladder, the ‘‘keyhole’’ sign, bilateral hydronephrosis, and oligohydramnios undergo detailed fetal urine electrolytes and invasive genetic testing before enrollment. Procedures are performed between 16 0/7 and 25 6/7 weeks at specialized fetal surgery centers after psychosocial evaluation and confirmation that the family has considered and declined termination. Maternal and fetal outcomes including renal function markers, amniotic fluid volume, survival to delivery, and neonatal status are tracked after the intervention.
Why it matters
Potential benefit: If successful, fetal cystoscopy could preserve fetal kidney function, restore amniotic fluid, reduce lung underdevelopment, and improve survival and neonatal outcomes.
How similar studies have gone: Previous case series and trials using fetal cystoscopy or vesicoamniotic shunts have shown improved survival in some patients but variable long-term kidney outcomes, so the approach has precedent but results remain mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pregnant women 2. Singleton pregnancy 3. Maternal age ≥ 18 years 4. Male fetus with LUTO, dilated bladder, "keyhole sign" and bilateral hydronephrosis 5. Oligohydramnios or Anhydramnios 6. Favorable urine analysis defined as urinary sodium is \< 100 milliequivalents per liter (mEq/L), chloride \< 90 mEq/L, and osmolality \< 200 milliosmoles per kilogram (mOsm/kg) after 20 weeks and in the absence of previous in utero intervention for the disease (vesicoamniotic shunt placement or fetal cystoscopy). 7. Absence of chromosomal abnormalities and associated anomalies 8. Gestational age at the time of the procedure will be between 16 0/7 weeks and 25 6/7 weeks 9. Normal karyotype by invasive testing (amniocentesis or Chorionic Villus Sampling (CVS)). Patients declining invasive testing will be excluded. 10. Family have considered and declined the option of termination of the pregnancy at less than 24 weeks. 11. Family meets psychosocial criteria, including sufficient social support and ability to understand requirements of the study. 12. Parents or guardian are willing to provide signed informed consent. Exclusion Criteria: 1. Fetal anomaly unrelated to LUTO 2. Congenital cardiac anomaly 3. Female fetus 4. Increased risk for preterm labor including short cervical length (\<1.5 cm), history of incompetent cervix with or without cerclage, and previous preterm birth 5. Placental abnormalities (previa, abruption, accreta) known at time of enrollment 6. Contraindications to surgery including previous hysterotomy in active uterine segment 7. Technical limitations precluding fetoscopic surgery, such as uterine fibroids, fetal membrane separation, uterine anomalies incompatible with fetoscopy 8. Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy 9. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment 10. Maternal medical condition that is a contraindication to surgery or anesthesia 11. Patient does not have health insurance to cover routine clinical care including prenatal care, prenatal ultrasound, amniocentesis, tocolysis, admission, delivery, and fetal vesico-amniotic shunting. The exception will be fetal cystoscopy which is considered an experimental procedure. 12. Inability to comply with travel and follow-up requirements of the trial 13. Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy 14. Patients declining invasive testing 15. Family does not meet psychosocial criteria including insufficient
Where it's running
-
University of Miami
Miami, Florida, United States Recruiting -
Mayo Clinic
Rochester, Minnesota, United States Terminated
Study contacts
- Principal investigator: Rodrigo Ruano, MD, PhD. — University of Miami
- Study coordinator: Rodrigo A Ruano, MD, PhD.
- Email: rodrigo.ruano@miami.edu
- Phone: 305.243.0769
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Compare three tools for removing large prostates: ThuFLEP, HoLEP, and B-TUEP
This trial tests whether three endoscopic techniques for large prostate removal are safe and effective in men with severe urinary symptoms who have not improved with medicines.
-
Using ultrasound to visualize kidney issues in children with congenital anomalies
This study is testing if special ultrasound techniques can help doctors see kidney problems in children with birth defects affecting their kidneys and urinary tract.
-
Amnioinfusion to help fetuses with kidney problems
This study is testing if giving extra fluid to pregnant women with fetuses that have serious kidney problems can help improve the babies' chances of survival and healthy development.
-
Examining the link between urine proteins and urinary symptoms in men with prostate enlargement
This study is testing how certain proteins in urine relate to urinary problems in older men with prostate enlargement and whether a specific surgery can help improve their symptoms.
-
Transplanting both a kidney and a bladder at the same time
This study is testing if it's possible to safely transplant both a kidney and a bladder at the same time in patients who have kidney problems caused by bladder issues.
-
Using amnioinfusions to treat pulmonary hypoplasia in fetuses
This study is testing if giving extra fluid to pregnant women with fetuses that have severe urinary problems can help improve lung development and kidney function in newborns.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.